Amicus Therapeutics, Inc.

NasdaqGM:FOLD Stock Report

Market Cap: US$3.2b

Amicus Therapeutics Future Growth

Future criteria checks 6/6

Amicus Therapeutics is forecast to grow earnings and revenue by 62.4% and 20.3% per annum respectively. EPS is expected to grow by 63.2% per annum. Return on equity is forecast to be 37.9% in 3 years.

Key information

62.4%

Earnings growth rate

63.2%

EPS growth rate

Biotechs earnings growth28.4%
Revenue growth rate20.3%
Future return on equity37.9%
Analyst coverage

Good

Last updated06 Sep 2024

Recent future growth updates

Recent updates

Amicus Therapeutics: A Compelling Investment In The Rare Disease Biotech Sector

Aug 16

Little Excitement Around Amicus Therapeutics, Inc.'s (NASDAQ:FOLD) Revenues

Jul 02
Little Excitement Around Amicus Therapeutics, Inc.'s (NASDAQ:FOLD) Revenues

Here's Why Amicus Therapeutics (NASDAQ:FOLD) Can Afford Some Debt

Jun 06
Here's Why Amicus Therapeutics (NASDAQ:FOLD) Can Afford Some Debt

Amicus Therapeutics: Too Cheap At Under $10 A Share

May 20

Amicus Therapeutics, Inc. (NASDAQ:FOLD) Looks Inexpensive But Perhaps Not Attractive Enough

Mar 27
Amicus Therapeutics, Inc. (NASDAQ:FOLD) Looks Inexpensive But Perhaps Not Attractive Enough

Amicus Therapeutics: Expect Improved Commercial Momentum In 2024

Feb 29

Amicus Therapeutics, Inc.'s (NASDAQ:FOLD) Share Price Could Signal Some Risk

Dec 19
Amicus Therapeutics, Inc.'s (NASDAQ:FOLD) Share Price Could Signal Some Risk

Amicus Therapeutics (NASDAQ:FOLD) Is Carrying A Fair Bit Of Debt

Jul 06
Amicus Therapeutics (NASDAQ:FOLD) Is Carrying A Fair Bit Of Debt

Amicus Therapeutics, Inc.'s (NASDAQ:FOLD) Revenues Are Not Doing Enough For Some Investors

May 14
Amicus Therapeutics, Inc.'s (NASDAQ:FOLD) Revenues Are Not Doing Enough For Some Investors

Does Amicus Therapeutics (NASDAQ:FOLD) Have A Healthy Balance Sheet?

Mar 23
Does Amicus Therapeutics (NASDAQ:FOLD) Have A Healthy Balance Sheet?

We Think Amicus Therapeutics (NASDAQ:FOLD) Has A Fair Chunk Of Debt

Dec 06
We Think Amicus Therapeutics (NASDAQ:FOLD) Has A Fair Chunk Of Debt

Amicus Therapeutics (NASDAQ:FOLD) Is Carrying A Fair Bit Of Debt

Aug 25
Amicus Therapeutics (NASDAQ:FOLD) Is Carrying A Fair Bit Of Debt

Amicus Therapeutics: AT-GAA Approval Delayed, I Will Continue Holding

Aug 10

Amicus Therapeutics Q2 2022 Earnings Preview

Aug 03

Is Amicus Therapeutics (NASDAQ:FOLD) Weighed On By Its Debt Load?

May 06
Is Amicus Therapeutics (NASDAQ:FOLD) Weighed On By Its Debt Load?

Amicus Therapeutics: An Inflection Point In Growth

Apr 27

Earnings and Revenue Growth Forecasts

NasdaqGM:FOLD - Analysts future estimates and past financials data (USD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/20268231962462538
12/31/20256416016818113
12/31/2024517-57192313
6/30/2024456-120-48-42N/A
3/31/2024423-147-88-81N/A
12/31/2023399-152-77-69N/A
9/30/2023372-174-162-153N/A
6/30/2023351-185-133-127N/A
3/31/2023337-204-131-126N/A
12/31/2022329-237-170-167N/A
9/30/2022323-264-159-156N/A
6/30/2022321-281-172-168N/A
3/31/2022318-270-192-188N/A
12/31/2021306-250-206-202N/A
9/30/2021294-239-185-182N/A
6/30/2021282-252-203-200N/A
3/31/2021267-254-201-198N/A
12/31/2020261-277-237-233N/A
9/30/2020246-295-254-241N/A
6/30/2020227-293-272-255N/A
3/31/2020209-325-298-280N/A
12/31/2019182-356-270-250N/A
9/30/2019160-345-264-253N/A
6/30/2019131-442-340-330N/A
3/31/2019109-419-337-329N/A
12/31/201891-349-306-300N/A
9/30/201873-340-318-312N/A
6/30/201864-293-233-228N/A
3/31/201849-279N/A-213N/A
12/31/201737-284N/A-214N/A
9/30/201725-273N/A-173N/A
6/30/201716-208N/A-165N/A
3/31/20179-211N/A-155N/A
12/31/20165-200N/A-150N/A
9/30/20162-184N/A-154N/A
6/30/2016N/A-175N/A-134N/A
3/31/2016N/A-152N/A-124N/A
12/31/2015N/A-132N/A-100N/A
9/30/2015N/A-110N/A-79N/A
6/30/20150-90N/A-73N/A
3/31/20151-77N/A-62N/A
12/31/20141-69N/A-52N/A
9/30/20142-60N/A-45N/A
6/30/20141-57N/A-44N/A
3/31/20141-58N/A-42N/A
12/31/20130-60N/A-46N/A
9/30/20130-57N/A-45N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: FOLD is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2.5%).

Earnings vs Market: FOLD is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: FOLD is expected to become profitable in the next 3 years.

Revenue vs Market: FOLD's revenue (20.3% per year) is forecast to grow faster than the US market (8.7% per year).

High Growth Revenue: FOLD's revenue (20.3% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: FOLD's Return on Equity is forecast to be high in 3 years time (37.9%)


Discover growth companies